Healthcare
Zai Lab Limited(ZLAB)
Live Price
Offline$18.18
+1.68% today
1Y Change
-52.60%
Window
Jun 23, 2025 β Jun 12, 2026
- Market Cap
- $2.39B
- Revenue Growth
- +15.3%
- EPS Growth
- +38.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 23, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zai Lab Limited (ZLAB) is a Healthcare stock with a market cap of $2.39B and listed on NASDAQ. The stock last traded around $18.18 and down 52.6% across the available one-year price window (Jun 23, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of +15.3%, EPS growth of +38.5%, a dividend yield of 0.0%. What stands out right now is revenue +15.3%, EPS +38.5%, free cash flow +42.5% with operating margin -49.9% and ROIC -23.3%. Valuation sits in the middle of the pack at price/sales 5.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZLAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.3% vs +7.6% peer median
Operating Margin
Below sector median
-49.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +12.6% and a revenue surprise of -8.1%.
The operating story is still moving forward
Revenue is running at +15.3% and EPS at +38.5%, with operating margin around -49.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +12.6% | -5.9% | +2.9% | -15.9% |
2026 Feb 26, 2026 | -4.5% | -2.4% | -2.0% | -11.1% |
2025 Nov 6, 2025 | -17.9% | -5.4% | -6.1% | -15.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLAB
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
ZLAB Max Drawdown
-59.76%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZLAB and SPY.
Company Overview
Zai Lab Limited
NASDAQ Global Market
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naΓ―ve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
- Leadership
- Ying Du
- IPO Date
- Sep 20, 2017
- Employees
- 1.9k
- Street Address
- Jinchuang Plaza
- Mailing
- Shanghai, 201210
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 6163 2588
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 5.2
- Price/Book
- 3.3
Growth
- Revenue
- +15.3%
- EPS
- +38.5%
- Free Cash Flow
- +42.5%
Profitability
- Gross Margin
- 58.5%
- Operating Margin
- -49.9%
- Net Margin
- -38.1%
- ROE
- -22.8%
- ROIC
- -23.3%
Balance Sheet
- Debt/Equity
- 0.33
- Current Ratio
- 2.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.